

**IDRI (Infectious Disease Research Institute) is a nonprofit, global health organization with a comprehensive approach to combatting infectious diseases, combining the high-quality science of a research organization with the product development capabilities of a biotech company. Our goal: to create new diagnostics, drugs and vaccines.**

**Founded in 1993 by Dr. Steven Reed, IDRI has 125 employees headquartered in Seattle with nearly 100 partners around the world. IDRI has had notable success providing solutions that have significantly reduced the global burden of disease, including diagnostic tests currently on the market. Our advanced product pipeline has the potential to save millions of lives.**



## **WHAT DIFFERENTIATES IDRI?**

### **APPLIED FOCUS.**

Unlike most not for profit research institutes, IDRI has fully integrated product development capabilities, ranging from early stage discovery to clinical trials, including GMP manufacturing. Because of this, IDRI is often the collaborator of choice for other research groups with early stage programs.

### **DEMONSTRATED DEVELOPMENT SUCCESS.**

IDRI has diagnostic products on the market. IDRI's diagnostic for Chagas disease antigens is currently commercialized by Abbott and several smaller companies, and is being used to help screen the U.S. blood supply for Chagas parasite contamination. IDRI has also developed diagnostics for leishmaniasis, currently distributed to the market by multiple licensing partners on four continents. Our most recent success is a diagnostic for leprosy, recently licensed for use in Brazil. We also have developed vaccines for TB and leishmaniasis, currently in clinical trials, and are in the discovery/development phase for new drugs to combat TB.


### **COMPREHENSIVE SOLUTIONS TO DISEASE PROBLEMS.**

IDRI has the internal scientific capability to approach seemingly intractable diseases with comprehensive solutions: diagnostics for early detection, allowing early drug therapy, coupled with vaccine development to ultimately eradicate disease. For those diseases addressed by IDRI, there is no other institution dedicated to global health with similar comprehensive capabilities.

### **UNIQUE POSITION RELATED TO ADJUVANT DEVELOPMENT FOR NEGLECTED DISEASES.**

Adjuvants are immune stimulators that can be combined with antigens to create vaccine products that have greater protection and increased activity at lower and fewer doses. IDRI's proprietary collection of adjuvant molecules, coupled with its expertise in adjuvant and adjuvant-antigen formulation, have resulted in a world leadership position in the adjuvant area. IDRI's adjuvant portfolio has broad uses for infectious diseases within IDRI's current areas of expertise (tuberculosis, leishmaniasis, malaria, influenza, and leprosy) as well as for the neglected diseases of interest pursued by our collaborative organizations.

PRODUCT PIPELINE



We target diseases that kill more than six million people each year.

Although these diseases have different symptoms, global footprints, and challenges, we have a singular goal for each program: developing diagnostics, vaccines, and drugs that save lives and improve health outcomes.

MANAGEMENT TEAM PERSONNEL

IDRI employs over 125 full-time personnel in its efforts, including many with advanced degrees. The management team is made up of experienced, highly regarded personnel from the biotechnology, nonprofit and research communities.

Chris Antony  
VP, Operations

Anna Marie Beckmann, PhD  
VP, Development & Regulatory

Darrick Carter, PhD  
VP, Adjuvant Technology

Rhea Coler, PhD  
VP, Preclinical Biology

Erik Iverson, JD, LLM  
President, Business & Operations

Rob Lin, PhD, CFA  
VP, Finance

Tanya Parish, PhD  
VP, Drug Discovery

Steven G. Reed, PhD  
Founder, President & Chief Scientific Officer

Thomas Vedvick, PhD  
VP, Formulation & Process Development

BOARD OF DIRECTORS

Bruce Carter, PhD  
Former President of ZymoGenetics

Gail Cassell, PhD  
Visiting Professor, Harvard

Michel De Wilde, PhD  
Consultant

Christopher Hentschel, PhD  
Partner  
Life Science Ventures  
Former CEO of Medicines for Malaria Venture

Erik Iverson, JD, LLM  
President, Business & Operations, IDRI

David Perry, MBA  
President/CEO, Symbiota

Franklyn G. Prendergast, MD, PhD  
Edmond & Marion Guggenheim Professor of Biochemistry & Molecular Biology  
Professor of Molecular Pharmacology & Experimental Therapeutics Mayo Medical School, Emeritus

Massimo Radaelli, PhD  
President/Founder  
Noventia Pharma/Bioakos

Steven G. Reed, PhD  
Founder/President/CSO  
Infectious Disease Research Institute

SELECT FUNDERS

Bill & Melinda Gates Foundation  
World Health Organization  
National Institutes of Health  
The MJ Murdock Charitable Trust  
Eli Lilly & Company

Paul G Allen Family Foundation  
Glaxo Smith Kline  
American Leprosy Missions  
BARDA (US HHS) / DARPA (US DOD)  
Wellcome Trust

2014 RESEARCH BUDGET: ~\$20 MILLION